ArticleAmerican journal of translational research2018
Novel cancer cell lines derived from primary breast tumors in Chinese patients.
Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- miR‑125a‑5p reverses epithelial‑mesenchymal transition and restores drug sensitivity by negatively regulating TAFAZZIN signaling in breast cancer.Molecular medicine reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although many breast cancer cell lines have been used for cancer research during the past several decades, few have originated from primary tumors in Asian patients. Moreover, the incidence of breast cancer has been increasing rapidly in China during this time period. Therefore, it is essential to establish breast cancer cell lines from Chinese patients. Here, we report the establishment of three new breast cancer cell lines, designated BC-023, BC-024, and BC-034, from breast carcinoma tissues of three Chinese patients. These breast cancer cell lines grew as adherent monolayers with characteristic epithelial morphology and were maintained continuously
Indexed as
Identifiers
30662642PMC6325518W2999464495What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.